5 Analysts Have This to Say About Arcus Biosciences
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) has received positive ratings from 5 analysts in the last quarter, with an average price target of $49.8, indicating a potential upside from the current price of $23.03. The average price target has increased by 22.96% from the previous average of $40.50.
August 24, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcus Biosciences has received positive ratings from 5 analysts, indicating a potential upside.
The positive ratings from analysts indicate a bullish sentiment towards Arcus Biosciences. The average price target of $49.8, which is significantly higher than the current price, suggests a potential upside. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100